Clinical trial
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma…
NCT00014677 · Neurocrine Biosciences, Industry · Completed
Key facts
| NCT number | NCT00014677 |
|---|---|
| Title | NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | Neurocrine Biosciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Procedure |
| Interventions | interleukin-4 PE38KDEL cytotoxin, conventional surgery |
| Start date | Mar 1, 2001 |
| Primary completion | Sep 1, 2002 |
| Completion | Jul 1, 2008 |
| First posted | Nov 13, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: